Eli Lilly and Company appoints Luca Visini Managing Director for its operations in India

Bengaluru, February 14, 2018: Multinational biopharmaceutical leader, Eli Lilly and Company, announce dearlier this year the appointment of Luca Visini as Managing Director of its Indian subsidiary, Eli Lilly and Company (India) Pvt. Ltd, effective February 1, 2018.Visini replaces Edgard Olaizola, who headed Lilly India operations from September2013 to January 2018 and will now be moving internally to a new role.

Visini joined Lilly in 2004 and held several strategic leadership roles in various functional departments out of Lilly headquarters in Indianapolis, the USA and Europe. From 2011 to 2014 he was the country manager for Lilly Romania. He is taking this executive role endowed with a diverse and solid management experience at Lilly.

Speaking about his new appointment,Visini said,“I am thrilled to have been given the opportunity to work hand in hand with our passionate Lilly India team to contribute inmaking life better for people across the country. I am taking the lead of Lilly India in a year that marks Lilly’s 25-year presence in India, and that will witness the launch of several innovative medications which will help answer unmet needs.

Lilly has a strong heritage and experience in the research, development and management of chronic diseases such as cancer and diabetes. We are determined to engage with all stakeholders in the healthcare field in India to help people live longer, healthier and more active lives.”

Visini is a native of Italy, and analumnus of SDA Bocconi School of Management and UniversitàdegliStudi di Bergamo in Italy.

For more than 140 years, Eli Lilly and Company has united caring with discovery to make life better around the world and has been committed to bringing high-quality medicines that meet real needs. In 1993, Eli Lilly and Company established its wholly-owned subsidiary Eli Lilly and Company (India) Pvt. Ltd.,headquartered in Gurgaon. Since then, Lilly India has expanded its operations considerably, making Lilly’s innovative medications available to those who need them in India.

Corporate Comm India(CCI Newswire)